Antibodies for thetreatment of melanoma aimed at enhancing key pathways of T cell activation(Cytotoxic T Lymphocyte-Associated Antigen 4, e.g. Ipilimumab), targeting tumorvasculature (e.g. Bevacizumab), or tumor-associated antigens (e.g. High MolecularWeight-Melanoma Associated Antigen, HMW-MAA) have demonstrated promise in clinicalstudies [13], [22], [23], [24]. Here, CTLA4 is linked to melanoma.